Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuronal neuropathy17.09.03.0190.000168%-
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.000112%-
Neuromyotonia10.04.05.008; 15.05.03.033; 16.32.01.008; 17.05.03.0160.000504%-
Encephalitis autoimmune10.04.10.012; 16.32.01.006; 17.06.05.0020.000112%-
Diabetic metabolic decompensation05.07.03.003; 14.07.03.0030.000168%-
Noninfective epididymitis21.09.02.0040.000560%-
Bone marrow infiltration01.05.01.0180.000112%-
Toxic leukoencephalopathy12.03.01.059; 17.13.02.0120.000168%-
Disorganised speech17.02.08.017; 19.19.02.0050.000224%-
Pseudocirrhosis09.01.04.009; 16.32.03.0270.000112%-
Pharyngeal paraesthesia17.02.06.035; 22.04.05.0180.000504%-
Non-cirrhotic portal hypertension09.01.06.019; 24.08.06.0030.000616%-
Tongue discomfort07.14.02.0190.000280%-
Administration site pain08.02.04.029; 12.07.04.0290.000224%-
Behaviour disorder19.01.01.0050.000112%-
Catheter site bruise08.02.02.014; 12.07.02.014; 23.03.11.029; 24.07.06.0270.000112%-
Catheter site swelling08.02.02.005; 12.07.02.0050.000280%-
Catheter site vesicles08.02.02.030; 12.07.02.030; 23.03.01.0320.000168%-
Ductal adenocarcinoma of pancreas07.21.09.011; 16.13.10.0060.000224%-
Fixed eruption08.01.06.025; 10.01.01.037; 23.03.05.0080.000112%-
Focal dyscognitive seizures17.12.02.0050.000168%-
Gallbladder rupture09.03.02.012; 12.01.17.0050.000224%-
Haemoperitoneum07.07.02.007; 12.01.17.007; 24.07.02.0650.000168%-
Haemophagocytic lymphohistiocytosis01.05.01.026; 10.02.01.077; 16.32.03.0380.000616%-
Hemiparaesthesia17.02.06.0450.000448%-
Hepatic cytolysis09.01.07.0360.000616%-
Hyperleukocytosis01.02.01.0180.000280%-
Hypersensitivity pneumonitis10.01.03.056; 22.01.01.0270.000168%-
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.001287%-
Infusion related hypersensitivity reaction10.01.03.058; 12.02.05.0550.000168%-
The 23th Page    First    Pre   23 24    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene